Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Health Catalyst (HCAT) Net Cash Flow (2018 - 2025)

Health Catalyst (HCAT) has disclosed Net Cash Flow for 8 consecutive years, with -$10.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Net Cash Flow fell 108.19% year-over-year to -$10.4 million, compared with a TTM value of -$287.9 million through Sep 2025, down 223.44%, and an annual FY2024 reading of $143.4 million, up 1525.9% over the prior year.
  • Net Cash Flow was -$10.4 million for Q3 2025 at Health Catalyst, up from -$291.3 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $126.3 million in Q3 2024 and bottomed at -$291.3 million in Q2 2025.
  • Average Net Cash Flow over 5 years is -$2.7 million, with a median of $527000.0 recorded in 2024.
  • The sharpest move saw Net Cash Flow surged 903.96% in 2021, then plummeted 55379.13% in 2025.
  • Year by year, Net Cash Flow stood at -$82.5 million in 2021, then surged by 90.4% to -$7.9 million in 2022, then soared by 242.17% to $11.3 million in 2023, then tumbled by 797.24% to -$78.6 million in 2024, then skyrocketed by 86.82% to -$10.4 million in 2025.
  • Business Quant data shows Net Cash Flow for HCAT at -$10.4 million in Q3 2025, -$291.3 million in Q2 2025, and $92.3 million in Q1 2025.